The FDA has granted a priority review status for Exa-cel, a gene therapy procedure looking to treat sickle cell. Approval decision drops Dec 8th. If approved, how do you feel the stock price of CRSP would be affected?
The FDA has granted a priority review status for Exa-cel, a gene therapy procedure looking to treat sickle cell. Approval decision drops Dec 8th. If approved, how do you feel the stock price of CRSP would be affected?
Leave a Reply